Immunomedics (NASDAQ: IMMU) reported Q1 EPS of ($0.17), $0.03 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $129.2 thousand versus the consensus estimate of $3.1 million.

For earnings history and earnings-related data on Immunomedics (IMMU) click here.